CURRENT POSITION

• Stuart Scott, Centre Director, UK NEQAS for Leucocyte Phenotyping (LI)
• UK NEQAS Board Divisional Representative Haematology Division
• Vice President for UK NEQAS Working Groups

PROFESSIONAL CAREER

• Stuart joined UK NEQAS for Leucocyte Immunophenotyping (LI) in 2012 and leads the development and delivery of External Quality Assessment (EQA) programmes supporting over 2,500 laboratories worldwide. His work focuses on ensuring robust performance standards for flow cytometric and molecular genetic assays across a range of haematological disorders, with particular interests in measurable residual disease monitoring and emerging molecular technologies.
• Before joining UK NEQAS LI, Stuart spent ten years as a Clinical Scientist at the Sheffield Diagnostics Genetics Service, eventually leading the molecular haemato-oncology service.

OTHER PROFESSIONAL ROLES INCLUDE

• Chair of MRD AML Standardisation Working Group (2022)
• UK NHSEI Acute Myeloid Leukaemia Measurable Residual Disease Working Group (2021-current)
• Novartis UK Myeloid-Leukaemia Molecular Monitoring Steering Committee (2018)
• Member of the European LeukaemiaNet Acute Myeloid Leukaemia Minimal Residual Disease Working Group member (2019)
• Specialist Advisor to the Royal College of Pathologists National Quality Assurance Advisory Panel for Genetics (2014-current)
• Advisor to the Technical Working Group Review of WHO Manual for Establishment of National EQA Scheme for Testing Centres (2015)
• Author /co author of a number of scientific peer reviewed publications covering various aspects of haemato-oncology genetics
• https://www.researchgate.net/profile/Stuart-Scott-4/research
• https://orcid.org/my-orcid?orcid=0000-0001-8182-3057